血浆EVs长链RNA预测非小细胞肺癌患者对新辅助免疫疗法的应答和生存率

核心信息

• 论文英文标题: Plasma extracellular vesicle long RNAs predict response to neoadjuvant immunotherapy and survival in patients with non-small cell lung cancer
• 期刊: Pharmacol Res
• 发表年份: 2023
• DOI: 10.1016/j.phrs.2023.106921
• PMID/PMCID: 37709184

研究概览

Neoadjuvant immunotherapy has brought new hope for patients with non-small cell lung cancer (NSCLC). Our results demonstrate that the exLR-based signature could accurately predict responses to neoadjuvant immunotherapy and prognosis in NSCLC patients.

核心发现

Neoadjuvant immunotherapy has brought new hope for patients with non-small cell lung cancer (NSCLC).

However, limited by the lack of clinically feasible markers, it is still difficult to select NSCLC patients who respond well and to predict patients' clinical outcomes before the treatment.

Before the treatment, we isolated plasma extracellular vesicles (EVs) from three cohorts (discovery, training and validation) of 78 NSCLC patients treated with neoadjuvant immunotherapy.

To identify differentially-expressed EV long RNAs (exLRs), we employed RNA-seq in the discovery cohort.

Echo Biotech 角色

血浆外泌体分离鉴定&长链RNA测序分析&qPCR检测验证

关联平台: Exoomics®, Research Reagents & Tools

关联服务与能力: Biofluid EV Isolation & Purification, EV Basic Characterization (TEM/NTA/WB), EV lncRNA/mRNA Sequencing, qPCR Validation, Research Reagent / Product Supply

关联产品或试剂: Exosupur® EV Isolation/Purification Kit

参考文献

原始论文: Plasma extracellular vesicle long RNAs predict response to neoadjuvant immunotherapy and survival in patients with non-small cell lung cancer Pharmacol Res. 2023. DOI: 10.1016/j.phrs.2023.106921. PMID/PMCID: 37709184.